Giant Cell Tumor of Tendon Sheath

A tumor arising in the SYNOVIAL MEMBRANE; SYNOVIAL BURSA; or TENDON sheath. It is characterized by OSTEOCLAST-like GIANT CELLS; FOAM CELLS; pigmented HEMOSIDERIN-laden MACROPHAGES and inflammatory infiltrate. It is classified either as diffuse or localized tenosynovitis.

Also Known As:

Fibrous Histiocytoma of Tendon Sheath; Localized Giant Cell Tumor of the Tendon Sheath; Localized Nodular Tenosynovitis; Localized Pigmented Villonodular Synovitis; Nodular Tenosynovitis; Tenosynovial Giant Cell Tumor; Localized Nodular Tenosynovitides; Nodular Tenosynovitides; Nodular Tenosynovitides, Localized; Nodular Tenosynovitis, Localized; Tenosynovitides, Localized Nodular; Tenosynovitides, Nodular; Tenosynovitis, Localized Nodular; Tenosynovitis, Nodular

Networked: 113 relevant articles (12 outcomes, 7 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Pigmented Villonodular Synovitis
2.	Neoplasms (Cancer)
3.	Benign Fibrous Histiocytoma (Dermatofibroma)
4.	Giant Cell Tumors (Giant Cell Tumor)
5.	Bone Cysts (Bone Cyst)

Experts

1.	Healey, John H: 9 articles (01/2022 - 07/2015)
2.	Wagner, Andrew J: 9 articles (11/2021 - 03/2012)
3.	Gelderblom, Hans: 6 articles (11/2021 - 03/2012)
4.	Stacchiotti, Silvia: 6 articles (11/2021 - 03/2012)
5.	Tap, William D: 6 articles (11/2021 - 07/2015)
6.	Keedy, Vicki L: 3 articles (04/2022 - 07/2015)
7.	Shuster, Dale: 3 articles (11/2021 - 01/2021)
8.	Zahir, Hamim: 3 articles (11/2021 - 01/2021)
9.	Palmerini, Emanuela: 3 articles (08/2021 - 01/2020)
10.	Wang, Qiang: 3 articles (08/2021 - 01/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Giant Cell Tumor of Tendon Sheath:

1.	pexidartinibIBA 01/01/2018 - "Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature." 10/07/2023 - "Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. " 04/01/2022 - "Pexidartinib is approved for treatment of adult symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. " 01/01/2021 - "Aim: Pexidartinib is approved in the USA for the treatment of symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery. " 09/01/2020 - "In August 2019, the FDA approved pexidartinib (TURALIO™, Daiichi Sankyo), the first systemic treatment option for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations that were not amenable to improvement with surgery. "
2.	Imatinib Mesylate (Gleevec)FDA Link 10/10/2019 - "Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor." 03/15/2012 - "Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis." 04/01/2008 - "Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)."
3.	Macrophage Colony-Stimulating FactorIBA 01/01/2022 - "Neoplastic synovial lining cells that coexpress podoplanin and CD90 overproduce CSF-1, driving tenosynovial giant cell tumor." 01/01/2022 - "Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor." 01/01/2019 - "Tenosynovial giant cell tumor (TGCT) is a rare, proliferative and inflammatory disease with activation of colony stimulating factor 1 (CSF1) expression, and exhibits abnormal proliferation of mononuclear cells, multinucleated cells and foam cells. " 10/01/2021 - "Tenosynovial giant cell tumor (TGCT) is a locally aggressive tumor with colony-stimulating factor 1 receptor (CSF1R) signal expression. " 06/01/2020 - "Tenosynovial giant cell tumor (TGCT) is a benign mesenchymal tumor arising from the synovium of tendon sheats and joints, driven by colony-stimulating factor 1 (CSF1) over-expression. "
4.	HemosiderinIBA 01/01/2018 - "Histologically, PVNS is a tenosynovial giant cell tumor, characterized by proliferation of two types of mononuclear cells - predominantly small, histiocyte-like cells and larger cells with dense cytoplasm, reniform or lobulated nucleus, with accompanying multinucleated giant cells and macrophages overloaded with hemosiderin that give typical image on MRI - currently selected as a gold standard for its diagnosis. " 08/01/2021 - "To determine the frequency with which MRI of tenosynovial giant cell tumor demonstrates hemosiderin, visible intralesional fat signal, and proximity to synovial tissue. " 01/01/2013 - "Histopathological examination of the resected specimen confirmed the diagnosis of localized pigmented villonodular synovitis, with the mass consisting of proliferation of fibrohistiocytic cells, abundant hemosiderin, foamy histiocytes, and occasional giant cells. " 05/01/2000 - "The cytologic features of localized tenosynovial giant cell tumor of tendon sheath (TGCT-L) include abundant mononuclear histiocytic cells occurring singly and in three-dimensional tissue fragments, hemosiderin within histiocytes and a few multinucleated giant cells. " 12/01/2023 - "Tenosynovial giant cell tumor, previously known as pigmented villonodular synovitis, is a benign low-grade fibrohistiocytic proliferation with hemosiderin deposits in synovial joints. "
5.	Monoclonal AntibodiesIBA 01/01/1988 - "An immunohistochemical study of six giant cell tumors of bone and eight related lesions (aneurysmal bone cyst, fibrous histiocytoma, and giant cell tumor of tendon sheath) was performed using a panel of monoclonal antibodies directed to the Ia and monocyte-macrophage lineage antigens. " 12/01/2004 - "Using a monoclonal antibody with a standard immunohistochemical technique on paraffin sections, we evaluated expression of Mitf in 89 various giant cell lesions including giant cell tumor of bone (n26), giant cell tumor of tendon sheath/pigmented villonodular synovitis (n24), giant cell reparative granuloma (n3), aneurysmal bone cysts (n11), chondroblastomas (n7), foreign body giant cell reaction (n10), and sarcoidosis (n8). "
6.	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/01/2019 - "Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin's lymphoma, and glioblastoma. "
7.	AntigensIBA 01/01/1988 - "An immunohistochemical study of six giant cell tumors of bone and eight related lesions (aneurysmal bone cyst, fibrous histiocytoma, and giant cell tumor of tendon sheath) was performed using a panel of monoclonal antibodies directed to the Ia and monocyte-macrophage lineage antigens. "
8.	emactuzumabIBA 01/01/2020 - "Subsequently, a dose of 1,000 mg q2w was used in the extension phase of a phase I study of emactuzumab in patients with advanced solid tumors or diffuse-type tenosynovial giant cell tumor. " 01/01/2020 - "PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor."
9.	Phosphotransferases (Kinase)IBA 10/15/2022 - "Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)." 07/30/2015 - "Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor." 01/01/2021 - "Pexidartinib is a kinase inhibitor that induces tumor response and improvements in symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell tumor (TGCT). " 05/01/2020 - "The success of MTAs comes mainly from antiangiogenic agents in various STS subtypes, from colony-stimulating factor-1 receptor inhibitor in tenosynovial giant cell tumor and neurotrophic tropomyocin receptor kinase (NTRK) inhibitors while others, such as cyclin-dependent kinase (CDK)-4 inhibitors, remain under evaluation. " 12/01/2020 - "Pexidartinib, an oral inhibitor of tyrosine kinases including colony stimulating factor 1 receptor (CSF-1R), KIT, and FLT3, is FDA approved in adults with tenosynovial giant cell tumor. "
10.	ClusterinIBA 03/01/2012 - "Analyze the immunophenotype of the different cells in the various subtypes of giant cell tumor of tendon sheath (GCTS) and investigate the value of clusterin in pathological diagnosis and histogenesis of giant cell tumor of tendon sheath. " 03/01/2012 - "[Value of clusterin expression in pathologic diagnosis and histogenesis of giant cell tumor of tendon sheath]." 08/01/2009 - "Immunostaining for clusterin was performed on 40 cases of tenosynovial giant cell tumor (11 localized and 29 diffuse). " 01/01/2019 - "Areas in malignant tenosynovial giant cell tumor resembling pleomorphic spindle cell sarcoma or osteo/chondrosarcoma showed loss of clusterin expression. " 01/01/2018 - "Clusterin, a widely expressed, tissue-specific glycoprotein, is a diagnostic marker of several tumor types, including anaplastic large cell lymphoma, follicular dendritic cell sarcoma, and tenosynovial giant cell tumor. "

Therapies and Procedures

1.	Therapeutics 01/01/2010 - "The results from this model support clinical trials of equivalent humanized agents and anti-CSF1R small molecule drugs in cases of tenosynovial giant cell tumor refractory to conventional local therapy." 12/29/2018 - "Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy." 06/01/2002 - "[Diagnosis and therapy of nodular tenosynovitis of the tendon sheath--case presentation]." 09/01/2012 - "In subtypes with a clear role of specific factors in the pathophysiology of disease, such as giant cell tumor of the bone and diffuse-type tenosynovial giant cell tumor, it is reasonable to treat with newer targeted therapies, when available, in place of chemotherapy when systemic treatment is needed to control disease. " 03/01/2000 - "Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence."
2.	Synovectomy 01/01/2023 - "One-Stage Synovectomies Result in Improved Short-Term Outcomes Compared to Two-Stage Synovectomies of Diffuse-Type Tenosynovial Giant Cell Tumor (D-TGCT) of the Knee: A Multicenter, Retrospective, Cohort Study." 11/01/2023 - "Outcomes of arthroscopic elbow synovectomy and neurolysis of the ulnar nerve for tenosynovial giant cell tumor in a young athlete: a case report and literature review." 01/07/2021 - "Open synovectomy treatment for intra- and extraarticular localized pigmented villonodular synovitis of the knee: a case report." 01/01/2019 - "Localized Pigmented Villonodular Synovitis of the Knee: Outcomes of Arthroscopic Synovectomy." 05/01/2017 - "Arthroscopically-assisted mini open partial synovectomy for the treatment of localized pigmented villonodular synovitis of the knee. "
3.	Radiotherapy 05/01/2023 - "Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy." 03/01/2004 - "A large, multiply recurrent tenosynovial giant cell tumor of the hand treated with resection and radiation therapy." 10/01/2012 - "Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery."
4.	Knee Replacement Arthroplasty (Total Knee Replacement) 01/01/2017 - "Prognosis of Advanced Tenosynovial Giant Cell Tumor of the Knee Diagnosed During Total Knee Arthroplasty." 11/01/2023 - "An unusual case report of tenosynovial giant cell tumor after unicompartmental knee arthroplasty presenting with recurrent hemarthrosis."
5.	Tattooing 08/01/2017 - "The histopathologic differential diagnosis in the absence of clinical history includes paint in an abrasion, foreign body reaction to tattoo, giant cell tumor of tendon sheath, and various neoplasms. " 02/01/1989 - "To detect LZ in these cells morphologically, I have done electron microscopic observations of the following skin diseases; sarcoidosis, lupus vulgaris, lupus miliaris disseminatus faciei (LMDF), tattoo granuloma, lichen nitidus, foreign body granuloma, granuloma annulare, xanthelasma, xanthoma tuberosum, xanthoma planum, juvenile xanthogranuloma, giant cell tumor of tendon sheath, dermatofibroma, malignant fibrous histiocytoma, dermatofibrosarcoma protuberans, granulation tissue of burn, hypertrophic scar, and histiocytosis X. From both the immunohistochemical and the electron microscopic features it was concluded that a) immunohistochemically LZ-positive cells from lesions of sarcoidosis, lupus vulgaris, LMDF and tattoo granuloma had a number of electron-lucent bodies (ELB) or microvesicles in their cytoplasm, b) lichen nitidus and xanthoma tuberosum had few LZ-positive cells and the ELB were not observed, and c) the other diseases were LZ-negative, and the ELB were also absent. "